Sage Therapeutics, Inc. (NASDAQ:SAGE) tinted gains of +1.55% (+2.56 points) to US$167.79. The volume of 0.4 Million shares climbed down over an trading activity of 551.73 Million shares. EPS ratio determined by looking at last 12 month figures is -7.25. Over the same time span, the stock marked US$195.97 as its best level and the lowest price reached was US$59.57. The corporation has a market cap of US$7.73 Billion.
Sage Therapeutics, Inc. (NASDAQ:SAGE)’s earnings per share has been growing at a 0 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at -57.7 percent while most common profitability ratio return on investment (ROI) was 0 percent. The company’s institutional ownership is monitored at 0 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 6 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 1.57. 8 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
PPDAI Group Inc. (NYSE:PPDF) is worth US$1.36 Billion and has recently risen 1.55% to US$4.59. The latest exchange of 1.38 Million shares is below its average trading activity of 586.2 Million shares. The day began at US$4.59 but the price moved to US$4.52 at one point during the trading and finally capitulating to a session high of US$4.65. The stock tapped a 52-week high of US$14.63 while the mean 12-month price target for the shares is US$11.24.
Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 2.18, and a price to sales ratio of 2.16. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown 0%. With an institutional ownership near 6.8%, it carries an earnings per share ratio of -1.26.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 2 brokerage firms polled by Factset Research. At present, 1 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 1 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.75.